litlas
ログインアカウント作成

Steven Coutré

1986–2022 年に発表

97
論文数
30,539
被引用数
80
h 指数
97
i10 指数

被引用数

Steven Coutré の年別被引用数1987 年: 被引用 1 件1988 年: 被引用 5 件1989 年: 被引用 4 件1990 年: 被引用 5 件1991 年: 被引用 2 件1992 年: 被引用 5 件1993 年: 被引用 8 件1994 年: 被引用 14 件1995 年: 被引用 7 件1996 年: 被引用 7 件1997 年: 被引用 11 件1998 年: 被引用 6 件1999 年: 被引用 11 件2000 年: 被引用 11 件2001 年: 被引用 5 件2002 年: 被引用 21 件2003 年: 被引用 60 件2004 年: 被引用 78 件2005 年: 被引用 82 件2006 年: 被引用 73 件2007 年: 被引用 90 件2008 年: 被引用 95 件2009 年: 被引用 94 件2010 年: 被引用 63 件2011 年: 被引用 84 件2012 年: 被引用 115 件2013 年: 被引用 122 件2014 年: 被引用 225 件2015 年: 被引用 374 件2016 年: 被引用 282 件2017 年: 被引用 351 件2018 年: 被引用 404 件2019 年: 被引用 1,239 件2020 年: 被引用 1,421 件2021 年: 被引用 1,361 件2022 年: 被引用 823 件2023 年: 被引用 563 件2024 年: 被引用 923 件2025 年: 被引用 350 件2026 年: 被引用 14 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,586 件、この内訳の 29.2%中国: 引用元論文 640 件、この内訳の 7.2%ドイツ: 引用元論文 634 件、この内訳の 7.2%イギリス: 引用元論文 612 件、この内訳の 6.9%イタリア: 引用元論文 542 件、この内訳の 6.1%フランス: 引用元論文 401 件、この内訳の 4.5%オーストラリア: 引用元論文 305 件、この内訳の 3.4%スペイン: 引用元論文 303 件、この内訳の 3.4%カナダ: 引用元論文 252 件、この内訳の 2.8%スイス: 引用元論文 219 件、この内訳の 2.5%オランダ: 引用元論文 200 件、この内訳の 2.3%スウェーデン: 引用元論文 163 件、この内訳の 1.8%
0%29.2%その他 22.7%

機関

分野

  • Medicine73.3%
  • Biochemistry, Genetics and Molecular Biology17.2%
  • Immunology and Microbiology6.2%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Chemistry0.8%
  • Computer Science0.4%
  • その他1.3%

トピック

  • Chronic Lymphocytic Leukemia Research13.5%
  • Lymphoma Diagnosis and Treatment7.9%
  • Acute Myeloid Leukemia Research5.9%
  • Chronic Myeloid Leukemia Treatments5.8%
  • Acute Lymphoblastic Leukemia research3.5%
  • Immunodeficiency and Autoimmune Disorders3.2%
  • その他60.2%

共著者

全論文

検索で開く
  1. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    著者: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 被引用: 1,562

  2. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

    著者: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Gilles Salles, William G. Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C. Byrd - The Lancet 2020 被引用: 612

  3. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

    著者: Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia - Blood Advances 2022 被引用: 269

  4. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    著者: Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Steven Coutré, Arti Hurria, Jennifer R. Brown, Gerard Lozanski, James S. Blachly, Hatice Gülçin Özer, Brittny Major‐Elechi, Briant Fruth, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J. Mandrekar, John C. Byrd - New England Journal of Medicine 2018 被引用: 952

  5. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 被引用: 2,249

  6. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    著者: Tait D. Shanafelt, Xin V. Wang, Neil E. Kay, Curtis A. Hanson, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, José F. Leis, Cong C. Zhang, Steven Coutré, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman - New England Journal of Medicine 2019 被引用: 738

  7. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

    著者: Tait D. Shanafelt, Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, José F. Leis, Cong Christine Zhang, Steven Coutré, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman, Neil E. Kay - Blood 2022 被引用: 237

  8. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

    著者: John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Christopher Pocock, Patrick Thornton, Federico Caligaris‐Cappio, Tadeusz Robak, Julio Delgado, Stephen J. Schuster, Marco Montillo, Anna Schuh, Sven de Vos, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Jeffrey J. Jones, Alvina D. Chu, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen - New England Journal of Medicine 2014 被引用: 1,617

  9. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    著者: Talha Munir, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Thomas J. Kipps, Carol Moreno, Marco Montillo, Jan A. Burger, John C. Byrd, Peter Hillmen, Sandra Dai, Anita Szőke, James P. Dean, Jennifer A. Woyach - American Journal of Hematology 2019 被引用: 473

  10. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    著者: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd - Leukemia 2022 被引用: 200

  11. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    著者: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 被引用: 1,684

  12. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    著者: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutré, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens‐Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen P. Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari H. Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G. Wierda - The Lancet Oncology 2016 被引用: 796

  13. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    著者: Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutré, Stephen Devereux, Sebastian Grosicki, Helen O. McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps - Leukemia 2019 被引用: 463

  14. Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia

    著者: Esther Benamu, Kiran Gajurel, Jill N. Anderson, Tullia Lieb, Carlos A. Gómez, Hon Seng, Romielle Aquino, Desiree Hollemon, David K. Hong, Timothy A. Blauwkamp, Mickey Kertesz, Lily Blair, Paul L. Bollyky, Bruno C. Medeiros, Steven Coutré, Simona Zompì, José G. Montoya, Stan Deresinski - Clinical Infectious Diseases 2021 被引用: 126

  15. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

    著者: Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, Matthew S. Davids, Michael Y. Choi, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Paul M. Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Steven Coutré, Jennifer A. Woyach, John C. Byrd - The Lancet Oncology 2017 被引用: 378

  16. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

    著者: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour, Steven Coutré, Wojciech Jurczak, Stephen P. Mulligan, Anna Schuh, Sarit Assouline, Clemens‐Martin Wendtner, Andrew W. Roberts, Matthew S. Davids, Johannes Bloehdorn, Talha Munir, Sebastian Böttcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer A. Arzt, Su Young Kim, Maria Verdugo, Gary Gordon, Michael Hallek, William G. Wierda - Journal of Clinical Oncology 2018 被引用: 313

  17. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

    著者: Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale L. Bixby, Steven Coutré, Marcos de Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan A. Jacoby, Jeffrey E. Lancet, Thomas W. LeBlanc, Gabriel N. Mannis, Guido Marcucci, Michael G. Martin, Alice S. Mims, Margaret O’Donnell, Rebecca L. Olin, Deniz Peker, Alexander E. Perl, Daniel A. Pollyea, Keith W. Pratz, Thomas Prébet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew J. Wieduwilt, Kristina M. Gregory, OCN, Lydia J. Hammond, Ndiya Ogba - Journal of the National Comprehensive Cancer Network 2019 被引用: 424

  18. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien - Clinical Cancer Research 2020 被引用: 183

  19. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

    著者: Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Vijaya Raj Bhatt, Dale L. Bixby, William Blum, Steven Coutré, Marcos de Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Steven D. Gore, Aric C. Hall, Patricia Kropf, Jeffrey E. Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Joseph O. Moore, Rebecca L. Olin, Deniz Peker, Daniel A. Pollyea, Keith W. Pratz, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Matthew J. Wieduwilt, Kristina M. Gregory, Ndiya Ogba - Journal of the National Comprehensive Cancer Network 2017 被引用: 655

  20. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

    著者: Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutré, Marie‐Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael M. Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger - Haematologica 2017 被引用: 258

  21. Acute Lymphoblastic Leukemia, Version 2.2015

    著者: Joseph Alvarnas, Patrick A. Brown, Patricia Aoun, Karen K. Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan D. Cassaday, Januario E. Castro, Peter F. Coccia, Steven Coutré, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary M. Kupfer, Mark R. Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina M. Gregory, Courtney Smith - Journal of the National Comprehensive Cancer Network 2015 被引用: 245

  22. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

    著者: Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven Coutré, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour - Blood 2019 被引用: 175

  23. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    著者: Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer - Journal of Clinical Oncology 2019 被引用: 221

  24. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O’Brien - Blood 2015 被引用: 656